SCHEMBL5356743

SCHEMBL5356743

CC(=O)OCC(F)(F)C(F)(F)F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.42
LMNA P02545 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CHRM5 P08912 2/20 0.34
CHRM1 P11229 2/20 0.34
CHRM3 P20309 2/20 0.34
TSHR P16473 2/20 0.34
HTT P42858 1/20 0.34
PGR P06401 1/20 0.34
CHRM2 P08172 1/20 0.34
CHRM4 P08173 1/20 0.34
HTR1A P08908 1/20 0.34
CHRNB2 P17787 1/20 0.34
TBXA2R P21731 1/20 0.34
CHRNB4 P30926 1/20 0.34
CHRNA3 P32297 1/20 0.34
CHRNA7 P36544 1/20 0.34
CHRNA4 P43681 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CHRNA10 Q9GZZ6 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12445294 0.90 ALDH1A1 (0.46) ALDH1A1LMNAHSD17B10CHRM5CHRM1
SCHEMBL5704616 0.86 ALDH1A1 (0.39) ALDH1A1LMNAHSD17B10CHRM5CHRM1
SCHEMBL14715844 0.84 ALDH1A1 (0.37) ALDH1A1LMNAHSD17B10CHRM5CHRM1
SCHEMBL16213957 0.83 ALDH1A1 (0.40) ALDH1A1LMNAHSD17B10CHRM5CHRM1
SCHEMBL20258482 0.82 THRB (0.37) ALDH1A1LMNAHSD17B10CHRM5CHRM1
SCHEMBL17832176 0.82 ALDH1A1 (0.33) ALDH1A1LMNAHSD17B10
SCHEMBL14281229 0.81 HTT (0.32) HTT
SCHEMBL333504 0.79
SCHEMBL610647 0.79 HTT (0.37) ALDH1A1HTT
SCHEMBL6876173 0.79 ALDH1A1 (0.46) ALDH1A1LMNAHSD17B10CHRM5CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9427777-B2 Process for producing charge retention medium ASAHI GLASS COMPANY, LIMITED (JP) 2016-08-30 US claimed
US-7195752-B2 Surfactant compounds and uses thereof GLAXO GROUP LIMITED (GB) 2007-03-27 US claimed
EP-1486203-A2 Surfactant compounds and uses thereof GLAXO GROUP LIMITED (GB) 2004-12-15 EP claimed
US-20040234556-A1 Surfactant compounds and uses thereof GLAXO GROUP LIMITED (GB) 2004-11-25 US claimed
EP-1411896-A2 SURFACTANT COMPOUNDS AND USES THEREOF GLAXO GROUP LIMITED (GB) 2004-04-28 EP claimed
WO-2003013610-A2 SURFACTANT COMPOUNDS AND USES THEREOF GLAXO GROUP LIMITED (GB) 2003-02-20 WO claimed
US-20250239647-A1 COMPOSITE SOLID ELECTROLYTE AND SECONDARY BATTERY INCLUDING THE SAME SAMSUNG ELECTRONICS CO., LTD. (KR) 2025-07-24 US disclosed
US-20220123241-A1 PREPARATION AND LAYER NeuDrive Llimited (GB) 2022-04-21 US disclosed
US-9427777-B2 Process for producing charge retention medium ASAHI GLASS COMPANY, LIMITED (JP) 2016-08-30 US disclosed
US-20150221987-A1 ELECTROLYTIC SOLUTION FOR NON-AQUEOUS SECONDARY BATTERY, AND NON-AQUEOUS ELECTROLYTIC SOLUTION SECONDARY BATTERY FUJIFILM CORPORATION (JP) 2015-08-06 US disclosed
EP-2648196-A1 CHARGE RETENTION MEDIUM Asahi Glass Company, Limited (JP) 2013-10-09 EP disclosed
EP-2648197-A1 METHOD FOR PRODUCING CHARGE RETENTION MEDIUM Asahi Glass Company, Limited (JP) 2013-10-09 EP disclosed
US-20130261248-A1 CHARGE RETENTION MEDIUM ASAHI GLASS COMPANY, LIMITED (JP) 2013-10-03 US disclosed
US-7544706-B2 Substituted imidazoles PFIZER LIMITED (GB) 2009-06-09 US disclosed
WO-2008121804-A1 USE OF A COMBINATION CHAIN TRANSFER AND ACTIVATING AGENT TO CONTROL MOLECULAR WEIGHT AND OPTICAL DENSITY OF PD CATALYZED NORBORNENE POLYMERS PROMERUS LLC (US) 2008-10-09 WO disclosed
US-20080125473-A1 SUBSTITUTED IMIDAZOLES PFIZER LIMITED (GB) 2008-05-29 US disclosed
US-20080119536-A1 SUBSTITUTED IMIDAZOLES PFIZER LIMITED (GB) 2008-05-22 US disclosed
US-20080004415-A1 Non-linear optically active molecules, their synthesis, and use OPTIMER PHOTONICS, INC. (US) 2008-01-03 US disclosed
US-20070167506-A1 SUBSTITUTED IMIDAZOLES PFIZER INC. (US) 2007-07-19 US disclosed
US-20070088029-A1 Tricycloundecane compounds useful as modulators of nuclear hormone receptor function BRISTOL-MYERS SQUIBB COMPANY 2007-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080125473-A1 SUBSTITUTED IMIDAZOLES ABL1, TYR, CYP3A4 ALDH1A1 617/4885LMNA 3030/4885HSD17B10 4048/4885
US-20070167506-A1 SUBSTITUTED IMIDAZOLES ABL1, TYR, CYP3A4 ALDH1A1 617/4885LMNA 3030/4885HSD17B10 4048/4885
US-20080119536-A1 SUBSTITUTED IMIDAZOLES ABL1, TYR, CYP3A4 ALDH1A1 617/4885LMNA 3030/4885HSD17B10 4048/4885
US-20040234556-A1 Surfactant compounds and uses thereof PFN1, SGMS1, SPTLC1 ALDH1A1 1123/4885LMNA 836/4885HSD17B10 1541/4885
US-20070088029-A1 Tricycloundecane compounds useful as modulators of nuclear hormone receptor function VDR, ESRRB, NR5A1 ALDH1A1 3634/4885LMNA 3299/4885HSD17B10 94/4885
US-20080004415-A1 Non-linear optically active molecules, their synthesis, and use INCENP, CYBA, PAICS ALDH1A1 378/4885LMNA 289/4885HSD17B10 1611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.